TY - JOUR
T1 - Plasma fetuin-A concentration, genetic variation in the AHSG gene and risk of colorectal cancer
AU - Nimptsch, Katharina
AU - Aleksandrova, Krasimira
AU - Boeing, Heiner
AU - Janke, Jürgen
AU - Lee, Young Ae
AU - Jenab, Mazda
AU - Kong, So Yeon
AU - Tsilidis, Konstantinos K.
AU - Weiderpass, Elisabete
AU - Bueno-De-Mesquita, H. Bas
AU - Siersema, Peter D.
AU - Jansen, Eugène H.J.M.
AU - Trichopoulou, Antonia
AU - Tjønneland, Anne
AU - Olsen, Anja
AU - Wu, Chunsen
AU - Overvad, Kim
AU - Boutron-Ruault, Marie Christine
AU - Racine, Antoine
AU - Freisling, Heinz
AU - Katzke, Verena
AU - Kaaks, Rudolf
AU - Lagiou, Pagona
AU - Trichopoulos, Dimitrios
AU - Severi, Gianluca
AU - Naccarati, Alessio
AU - Mattiello, Amalia
AU - Palli, Domenico
AU - Grioni, Sara
AU - Tumino, Rosario
AU - Peeters, Petra H.
AU - Ljuslinder, Ingrid
AU - Nyström, Hanna
AU - Brändstedt, Jenny
AU - Sánchez, María José
AU - Gurrea, Aurelio Barricarte
AU - Bonet, Catalina Bonet
AU - Chirlaque, María Dolores
AU - Dorronsoro, Miren
AU - Quirõs, José Ramõn
AU - Travis, Ruth C.
AU - Khaw, Kay Tee
AU - Wareham, Nick
AU - Riboli, Elio
AU - Gunter, Marc J.
AU - Pischon, Tobias
N1 - Publisher Copyright:
© 2015 UICC.
PY - 2015/8/15
Y1 - 2015/8/15
N2 - Fetuin-A, also referred to as α2-Heremans-Schmid glycoprotein (AHSG), is a liver protein known to inhibit insulin actions. Hyperinsulinemia is a possible risk factor for colorectal cancer; however, the role of fetuin-A in the development of colorectal cancer is unclear. We investigated the association between circulating fetuin-A and colorectal cancer risk in a nested case-control study within the European Prospective Investigation into Cancer and Nutrition. Fetuin-A concentrations were measured in prediagnostic plasma samples from 1,367 colorectal cancer cases and 1,367 matched controls. In conditional logistic regression models adjusted for potential confounders, the estimated relative risk (95% confidence interval) of colorectal cancer per 40 μg/mL higher fetuin-A concentrations (approximately one standard deviation) was 1.13 (1.02-1.24) overall, 1.21 (1.05-1.39) in men, 1.06 (0.93-1.22) in women, 1.13 (1.00-1.27) for colon cancer and 1.12 (0.94-1.32) for rectal cancer. To improve causal inference in a Mendelian Randomization approach, five tagging single nucleotide polymorphisms of the AHSG gene were genotyped in a subset of 456 case-control pairs. The AHSG allele-score explained 21% of the interindividual variation in plasma fetuin-A concentrations. In instrumental variable analysis, genetically raised fetuin-A was not associated with colorectal cancer risk (relative risk per 40 μg/mL genetically determined higher fetuin-A was 0.98, 95% confidence interval: 0.73-1.33). The findings of our study indicate a modest linear association between fetuin-A concentrations and risk of colorectal cancer but suggest that fetuin-A may not be causally related to colorectal cancer development. What's new? Fetuin-A is a liver protein associated with insulin resistance, but with no defined role yet in colorectal cancer. In this prospective study, the authors uncover a modest linear association between fetuin-A levels and higher risk of colorectal cancer, but this was only observed in male participants. In addition, no association was observed between fetuin-A variants and colorectal cancer risk in a Mendelian randomization analysis, arguing against a direct role of fetuin-A in colorectal carcinogenesis.
AB - Fetuin-A, also referred to as α2-Heremans-Schmid glycoprotein (AHSG), is a liver protein known to inhibit insulin actions. Hyperinsulinemia is a possible risk factor for colorectal cancer; however, the role of fetuin-A in the development of colorectal cancer is unclear. We investigated the association between circulating fetuin-A and colorectal cancer risk in a nested case-control study within the European Prospective Investigation into Cancer and Nutrition. Fetuin-A concentrations were measured in prediagnostic plasma samples from 1,367 colorectal cancer cases and 1,367 matched controls. In conditional logistic regression models adjusted for potential confounders, the estimated relative risk (95% confidence interval) of colorectal cancer per 40 μg/mL higher fetuin-A concentrations (approximately one standard deviation) was 1.13 (1.02-1.24) overall, 1.21 (1.05-1.39) in men, 1.06 (0.93-1.22) in women, 1.13 (1.00-1.27) for colon cancer and 1.12 (0.94-1.32) for rectal cancer. To improve causal inference in a Mendelian Randomization approach, five tagging single nucleotide polymorphisms of the AHSG gene were genotyped in a subset of 456 case-control pairs. The AHSG allele-score explained 21% of the interindividual variation in plasma fetuin-A concentrations. In instrumental variable analysis, genetically raised fetuin-A was not associated with colorectal cancer risk (relative risk per 40 μg/mL genetically determined higher fetuin-A was 0.98, 95% confidence interval: 0.73-1.33). The findings of our study indicate a modest linear association between fetuin-A concentrations and risk of colorectal cancer but suggest that fetuin-A may not be causally related to colorectal cancer development. What's new? Fetuin-A is a liver protein associated with insulin resistance, but with no defined role yet in colorectal cancer. In this prospective study, the authors uncover a modest linear association between fetuin-A levels and higher risk of colorectal cancer, but this was only observed in male participants. In addition, no association was observed between fetuin-A variants and colorectal cancer risk in a Mendelian randomization analysis, arguing against a direct role of fetuin-A in colorectal carcinogenesis.
KW - AHSG
KW - colorectal cancer
KW - fetuin-A
UR - http://www.scopus.com/inward/record.url?scp=84931566002&partnerID=8YFLogxK
U2 - 10.1002/ijc.29448
DO - 10.1002/ijc.29448
M3 - Article
C2 - 25611809
AN - SCOPUS:84931566002
SN - 0020-7136
VL - 137
SP - 911
EP - 920
JO - International Journal of Cancer
JF - International Journal of Cancer
IS - 4
ER -